<DOC>
	<DOCNO>NCT00874419</DOCNO>
	<brief_summary>Epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR TKIs ) erlotinib prove effective second third line therapy advance non-small cell lung cancer ( NSCLC ) .It well tolerate without side effect usually associate chemotherapy . The mutation EGFR exon 19 21 report associate efficacy EGFR TKIs.Based encouraging preliminary result Spanish lung cancer group ' prospective study report efficacy Tarceva first line treatment metastatic NSCLC patient EGFR mutation would delay disease progression , prolong overall survival well tolerate , medium Progression-free survival ( PFS ) around 12 month OS reach 24 months，our study design compare PFS patient mutant EGFR treat gemcitabine/carboplatin erlotinib first-line setting . We assume 11 month PFS Tarceva arm versus 6 month chemotherapy arm a=0.025 ( alpha-spend interim analysis ) , 80 % power 12 month enrolment period , 12 month FU duration calculate sample size . The sample size 69 pair . Considering 10 % drop-out rate , final sample size 152 patients.So , chemo-naive stag IIIb/IV patient EGFR mutation exon 19 21 enrol open-label , randomize , multicenter phase III study .</brief_summary>
	<brief_title>Erlotinib Versus Gemcitabine/Carboplatin Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor ( EGFR ) Exon 19 21 Mutation</brief_title>
	<detailed_description>Primary Outcome Measures : Progression-free survival ( PFS ) Secondary Outcome Measures : Overall response rate ( ORR ) , overall survival ( OS ) , quality life ( QOL ) , etc . Estimated Enrollment : 160 Study Start Date : August 2008 Estimated Study Completion Date : August 2010 The patient randomize follow two arm : Arm A : erlotinib 150mg per day disease progression intolerable toxicity . Arm B : Gemcitabine ( 1000mg/m2 , IV , d1 d8 ) plus Carboplatin ( AUC=5 , IV d1 ) repeat every 3 week 4 cycle .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Stage IIIB ( cytological confirm malignant pleural effusion pericardial effusion ) histopathological cytological confirm stage IV NSCLC relapse complete resection . 2 . EGFR exon19 deletion exon 21 L858R mutation DNA direct PCR sequence use fresh tumor sample paraffin embed tumor sample . 3 . Measurable lesion define RECIST criterion . 4 . Palliative radiotherapy allow finish 3 week first drug administration , target lesion include radiotherapy field . 5 . Patients operation allow operation 4 week first drug administration 6 . Men woman least 18 year age . 7 . ECOG Performance status 0 2 . 8 . Estimated life expectancy least 12 week . 9 . Patient compliance geographic proximity allow adequate followup . 10 . Adequate organ function test 7 day first drug administration : hemoglobin ≥9 g/dL , absolute neutrophil count ( ANC ) ≥1.5*109/L , platelet ≥100 *109/L , bilirubin ≤1.5ULN , alkaline phosphatase ( AP ) , aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤2.5 upper limited number ( ULN ) ( AP , AST , ALT ≤5ULN acceptable liver tumor involvement ) .INR≤1.5 , APTT normal range ( 1.2DLN1.2ULN ) , creatinine ≤1.5ULN . 11 . Informed consent patient . 1 . Have receive systemic anticancer therapy , include Cytotoxic drug , target therapy , experimental treatment , adjuvant neoadjuvant therapy ( except disease relapse 6 month final drug ) 2 . Wild type EGFR . 3 . Uncontrolled pericardial pleural effusion prior study entry . 4 . History cardiovascular disease : Congestive Heart Failure &gt; grade II NYHA . Unstable angina patient ( angina symptom rest ) new occurrence angina ( begin last 3 month ) myocardial infarction happen last 6 month 5 . Brain metastasis ( control brain metastasis steroid free need exclude ) . 6 . HIV infection 7 . Active infection , &gt; grade 2 Common Terminology Criteria Adverse Events ( CTCAE ) version 3 . 8 . A history operation serious traumatic 3 week first drug administration 9 . Patient malignant tumor except NSCLC 5 year previous study entry . Excluding cervical carcinoma situ , cure basal cell carcinoma , bladder epithelial tumor [ include Ta Tis ] 10 . Mixed small cell lung cancer 11 . Unable swallow drug . 12 . Malabsorption 13 . Pregnant child breast feed woman 14 . Childbearing patient use reliable method contraception study entry , process study within 30 day discontinuation study . Reliable contraceptive method determine principal investigator designate officer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>EGFR mutation</keyword>
	<keyword>EGFR-TKI</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>